Item 2.02 Results of Operations and Financial Condition.

The information provided in Item 7.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.02.

Item 7.01 Regulation FD Disclosure.

On January 13, 2022, Landos Biopharma, Inc. (the "Company") announced that its estimated cash, cash equivalents and short-term investments balance as of December 31, 2021 was approximately $91.0 million.

The Company's estimate of its cash position is preliminary and unaudited, represents management estimates as of the date of this Current Report on Form 8-K and are subject to completion of the Company's financial closing procedures. As a result, the Company's actual financial results may differ materially from the preliminary estimated financial information set forth above. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimate of the Company's cash position.

The information in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Any statements in this report about future expectations, plans and prospects for the Company and other statements containing the words "anticipate," "estimate," "expect," "may," "will," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the Company identifies items during its financial statement closing process that result in adjustments to the estimates, preliminary figures and guidance included in this report and other factors discussed in the "Risk Factors" section of the Company's most recent Form 10-K or Form 10-Q filed with the SEC and in the Company's other filings from time to time with the SEC. In addition, the forward-looking statements included in this report represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses